1423119-98-5 Usage
Description
Dabrafenib-D9 is a deuterated form of the drug dabrafenib, a medication used for the treatment of specific types of cancer, particularly melanoma with certain genetic mutations. This specifically labeled form of dabrafenib has been modified with deuterium atoms, a stable isotope of hydrogen, to enhance the drug's properties such as increasing its half-life in the body or improving its efficacy. Dabrafenib-D9 is utilized in preclinical and clinical studies to study the pharmacokinetics and metabolism of the drug, allowing for more accurate tracking and understanding of the drug's behavior in the body, which can ultimately lead to improved treatment outcomes for patients with cancer.
Uses
Used in Pharmaceutical Industry:
Dabrafenib-D9 is used as a deuterated drug for the treatment of melanoma with specific genetic mutations, enhancing the drug's properties and improving its efficacy in cancer treatment.
Used in Preclinical and Clinical Research:
Dabrafenib-D9 is used as a specifically labeled form of dabrafenib for studying the pharmacokinetics and metabolism of the drug, enabling more accurate tracking and understanding of the drug's behavior in the body.
Used in Cancer Treatment:
Dabrafenib-D9 is used as a medication for the treatment of melanoma with certain genetic mutations, providing enhanced properties and improved efficacy compared to the non-deuterated form of the drug.
Check Digit Verification of cas no
The CAS Registry Mumber 1423119-98-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,2,3,1,1 and 9 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1423119-98:
(9*1)+(8*4)+(7*2)+(6*3)+(5*1)+(4*1)+(3*9)+(2*9)+(1*8)=135
135 % 10 = 5
So 1423119-98-5 is a valid CAS Registry Number.
1423119-98-5Relevant articles and documents
Deuterated Benzene Sulfonamide Thiazole Compounds
-
, (2013/03/26)
Deuterated forms of N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide and pharmaceutical compositions containing the same.
